Which is the original manufacturer of pazopanib/pazopanib?

Pazopanib is an oral multi-target tyrosine kinase inhibitor (TKI) mainly used for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. It was originally developed and launched by the British pharmaceutical giant GlaxoSmithKline (GSK). As the world's leading innovative pharmaceutical company, GlaxoSmithKline has accumulated profound R&D capabilities in the field of targeted tumor therapy. Pazopanib is one of its important achievements in the field of small molecule targeted drugs. In 2009, the drug was first approved by the FDA for the treatment of advanced kidney cancer in the United States, and was subsequently approved in the European Union, Japan and other countries. The product name is often "Votrient". This trade name is also registered by GSK and is widely used in the international market.

As time went by, GlaxoSmithKline transferred part of its oncology drug business to Novartis (Novartis) due to strategic adjustments. Therefore, starting from 2015, the commercial operation rights of pazopanib in many markets around the world have been taken over by Novartis, which also means that in practical clinical applications, Novartis has been responsible for the marketing and supply of pazopanib that many doctors and patients have come into contact with. In the Chinese market, the drug was introduced by GlaxoSmithKline as an imported originator in the early days. Later, as the drug was negotiated and entered into the medical insurance list, the price was significantly reduced and patient accessibility was improved.

In addition, as patents gradually expire, generic versions of pazopanib have gradually emerged in many countries and regions. Especially in India, Bangladesh, Laos and other places, many generic drug manufacturers have launched cheaper versions. Although the ingredients of these generic drugs are consistent with the original drugs, since they have not yet been officially approved by the China Food and Drug Administration (NMPA), domestic patients who want to purchase them through formal channels still mainly use the original drugs. In summary, the original drug manufacturer of pazopanib is GlaxoSmithKline, but the current commercial operations and supply work in multiple markets around the world are continued by Novartis. The relevant information has important reference value for identifying drug sources and selecting treatment options.

Reference materials:https://www.votrient.com/